As expected and serving as a control, Vemurafenib as a single agent was found to only inhibit melanoma lines carrying BRAF V600E/K mutations, which signal as BRAF monomers and are thus sensitive to type 1.5 RAF inhibitors that specifically inhibit RAF monomers (Figure 1a). The gene discussed is BRAF; the disease is melanoma.